Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-response study of oral UK-390,957 in men with premature ejaculation
2004-000244-24Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in premature ejaculation (PE) comparing UK-390,957 dose groups with Placebo (2 arms). Primary endpoint: Intravaginal ejaculatory latency time (IELT) at Week 8. Started Jul 2004; status: completed.
02
Drugs
UK-390957
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on 2004-000244-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000244-24.